Research Synthesis: Longevity Lifespan Rates

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Surface the substantive tension between mechanistic/preclinical positive lifespan signals and the null/adjacent clinical evidence as an explicit disagreement in the Tensions and Gaps section, rather than reporting '0 cross-study disagreements.'
2. Reconcile the Longevity outcome class count (n=3) with the broader set of lifespan-relevant sources cited throughout the manuscript; either expand the Longevity class or explain the routing logic that places most lifespan-extension sources outside the Longevity class.
3. Clarify the phrase 'negative signals in no dominant outcome class' in the abstract to state plainly whether any negative findings were identified and where.
4. Add per-source risk-of-bias ratings to the Findings Map or as a supplementary table.
5. Audit the search summary to include query-level hit counts and final inclusion/exclusion counts tied to the funnel.

Major issues

• The abstract and Evidence Landscape state '0 cross-study disagreements across the evidence base,' yet the Tensions and Gaps section also says 'resolving 0 disagreement(s) narratively.' This is internally consistent only if no disagreements were actually found. However, the corpus mixes preclinical lifespan extension signals (positive: Yu 2025, Hao 2026, Zhang 2025, Naaz 2024, Gong 2026, Guo 2025, Vujovic 2026 mechanistic) against a null/adjacent contextual evidence class (6/8 sources with null signal). This is a substantive tension between mechanistic positive signals and null clinical/adjacent findings that the manuscript does not surface as a disagreement. The '0 disagreements' framing appears to be a definitional artifact rather than an honest representation of the evidence tension.
• The Findings Map reports only '3 included sources' in the Longevity class but the cited Longevity-relevant findings span many more sources (Yu 2025, Hao 2026, Zhang 2025, Naaz 2024, Xu 2026, Gong 2026, Guo 2025, Vujovic 2026, Traa 2024, Ayyadevara 2014, Munro 2019, Medford 2019). The narrow 3-source Longevity outcome class does not map transparently to the corpus actually discussed in Limitations and elsewhere.
• The abstract states 'negative signals in no dominant outcome class' — this phrasing is awkward and does not convey what (if any) negative findings exist; it reads as a placeholder.

Minor issues

• Search Summary lists queries but does not state date ranges or hit counts per query, limiting auditability.
• Risk-of-bias appraisal is mentioned (Cochrane RoB-2, ROBINS-I, AMSTAR-2) but per-source ratings are not surfaced in the manuscript.
• The funnel table includes 'Mixed partial-or-none' (229) and 'Partial-only' (60) rows whose relationship to the final 13 admitted sources is not clearly explained; the text says these are 'separate claim-binding audit buckets, not additive exclusion totals' but the accounting is hard to follow.
• Several sources are dated 2026 (Vujovic 2026, Hao 2026, Xu 2026, Gong 2026) which is plausible given the stated retrieval date but should be flagged as forward-dated relative to the reviewer perspective.
• The Limitations section cites Ioannidis 2005 and Anisimov 2008 as 'Ioannidis 2005' and 'Anisimov 2008' but these are not in the source bundle; they are referenced as authority but not in the citable evidence base.
• Ayyadevara 2014 is 11 years old and somewhat dated for a fast-moving field; its inclusion vs. exclusion rationale is not given.

Reviewer note

This evidence map on longevity lifespan rates is a credible thin-corpus evidence brief with a bounded scope, source-attributed findings, and an honest Limitations section that names the absence of human mortality RCTs. The Tensions and Gaps section is present, and the manuscript does not collapse into a single clinical recommendation, which is appropriate for the evidence-map genre. However, there are substantive issues. The most important is the claim of '0 cross-study disagreements.' The corpus contains strong mechanistic/preclinical positive signals (SeMSN, curcumin in yeast, decanoic acid in Drosophila, EDL in C. elegans, microbial interventions, metformin mechanisms) alongside a dominant null contextual-adjacent evidence class (6/8 sources null). That pattern is a real cross-class tension, and calling it zero disagreements obscures rather than maps the heterogeneity. The Tensions and Gaps section should explicitly surface this mechanistic-vs-clinical gap rather than leaving it implicit. The Longevity outcome class count (n=3) is inconsistent with the broader use of lifespan-relevant sources across the manuscript, and the routing logic is not explained. Several sources dated 2026 are included given the retrieval window, which is acceptable but worth flagging. Overall the manuscript is mostly correct and salvageable with bounded edits — primarily clarifying the disagreement framing, reconciling the outcome-class counts, and tightening the search/screening audit trail. Recommend revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis